ITMI981889A0 - Cerotto transdermico - Google Patents

Cerotto transdermico

Info

Publication number
ITMI981889A0
ITMI981889A0 IT98MI001889A ITMI981889A ITMI981889A0 IT MI981889 A0 ITMI981889 A0 IT MI981889A0 IT 98MI001889 A IT98MI001889 A IT 98MI001889A IT MI981889 A ITMI981889 A IT MI981889A IT MI981889 A0 ITMI981889 A0 IT MI981889A0
Authority
IT
Italy
Prior art keywords
transdermal patch
transdermal
patch
Prior art date
Application number
IT98MI001889A
Other languages
English (en)
Inventor
Allison Burton Scott
Tata Shahnaz
Original Assignee
Bertek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25440520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITMI981889(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bertek Inc filed Critical Bertek Inc
Publication of ITMI981889A0 publication Critical patent/ITMI981889A0/it
Publication of ITMI981889A1 publication Critical patent/ITMI981889A1/it
Application granted granted Critical
Publication of IT1302020B1 publication Critical patent/IT1302020B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT1998MI001889A 1997-08-21 1998-08-12 Cerotto transdermico. IT1302020B1 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/918,526 US5948433A (en) 1997-08-21 1997-08-21 Transdermal patch

Publications (3)

Publication Number Publication Date
ITMI981889A0 true ITMI981889A0 (it) 1998-08-12
ITMI981889A1 ITMI981889A1 (it) 2000-02-12
IT1302020B1 IT1302020B1 (it) 2000-07-20

Family

ID=25440520

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1998MI001889A IT1302020B1 (it) 1997-08-21 1998-08-12 Cerotto transdermico.

Country Status (5)

Country Link
US (1) US5948433A (it)
CA (1) CA2245366C (it)
DE (1) DE19837902B4 (it)
GB (1) GB2328375B (it)
IT (1) IT1302020B1 (it)

Families Citing this family (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834007C1 (de) * 1998-07-29 2000-02-24 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung
KR20010036685A (ko) * 1999-10-11 2001-05-07 김윤 펜타닐을 함유하는 매트릭스형 경피투여제
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
CN102327253A (zh) * 2000-04-26 2012-01-25 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
EP1757280A1 (en) 2001-03-16 2007-02-28 ALZA Corporation Transdermal patch for administering sufentanyl
DK1381352T3 (da) * 2001-03-16 2007-07-09 Alza Corp Plaster til transdermal indgivelse af fentanyl
CA2445086C (en) 2001-05-01 2008-04-08 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
ES2587187T3 (es) 2001-05-01 2016-10-21 A. V. Topchiev Institute Of Petrochemical Synthesis Composición bioadhesiva absorbente de agua bifásica
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
WO2003024450A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2003063927A2 (en) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
AU2002366796A1 (en) * 2001-12-19 2003-07-09 Eisai Co. Ltd Methods using proton pump inhibitors
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
MXPA04010612A (es) 2002-04-23 2005-07-14 Alza Corp Sistemas analgesicos transdermicos con potencial reducido de abuso.
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AU2003229016A1 (en) * 2002-05-10 2003-11-11 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
AU2003241464A1 (en) * 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7217853B2 (en) 2002-05-24 2007-05-15 Corium International, Inc. Composition for cushions, wound dressings and other skin-contacting products
BRPI0311383B1 (pt) * 2002-05-31 2016-05-24 Sabalo N V solução aquosa de ácido bórico e ácido silícico não coloidal, e, métodos para preparar a mesma, para o tratamento de plantas ou árvores, para o tratamento de alimento e para o tratamento de cosméticos , cremes terapêuticos, unguentos, xampus ou géis.
CA2490692A1 (en) 2002-06-27 2004-01-08 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040086551A1 (en) * 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
PT1594483E (pt) 2003-02-21 2006-12-29 Schering Ag Penso transdérmico estável aos uv
ATE487492T1 (de) * 2003-02-27 2010-11-15 Eisai R&D Man Co Ltd Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
US7244739B2 (en) * 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
AU2004266705A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20070059351A1 (en) * 2003-10-17 2007-03-15 Murrell George A C Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods
US20070053966A1 (en) * 2003-10-17 2007-03-08 Robert Ang Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue
US20060286159A1 (en) * 2003-10-17 2006-12-21 Calvert Murrell George A Treatment of persistent active tendinopathy using transdermal glyceryl trinitrate providing durability of effect
US20060286158A1 (en) * 2003-10-17 2006-12-21 Calvert Murrell George A Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents
KR20060120678A (ko) 2003-10-30 2006-11-27 알자 코포레이션 남용될 가능성이 감소된 경피용 진통제 시스템
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
JP4881006B2 (ja) * 2004-01-20 2012-02-22 ニプロパッチ株式会社 ツロブテロール貼付剤
CA2554716A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
WO2005074894A1 (en) 2004-01-30 2005-08-18 Corium International Rapidly dissolving film for delivery of an active agent
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2005113523A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2006009876A2 (en) * 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
JP2008505916A (ja) * 2004-07-09 2008-02-28 メタバシス・セラピューティクス・インコーポレイテッド チロシンホスファターゼの酸素／窒素複素環阻害剤
CN103497713B (zh) 2004-08-05 2018-07-17 考里安国际公司 粘合剂组合物
JP4745747B2 (ja) * 2004-08-12 2011-08-10 日東電工株式会社 フェンタニル含有貼付製剤
JP4824963B2 (ja) * 2004-08-12 2011-11-30 日東電工株式会社 貼付材及び貼付製剤
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ584773A (en) 2004-09-17 2012-07-27 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
PL1814531T3 (pl) * 2004-10-21 2010-11-30 Durect Corp Transdermalne systemy dostarczania
US8252319B2 (en) * 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US20080306041A1 (en) * 2005-01-21 2008-12-11 Garvey David S Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
JP2008530226A (ja) * 2005-02-16 2008-08-07 ニトロメッド インコーポレーティッド 抗微生物化合物の有機酸化窒素供与体塩、組成物、および使用法
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
AU2006218766A1 (en) * 2005-02-28 2006-09-08 Nicox S.A. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
AU2006223392A1 (en) * 2005-03-09 2006-09-21 Nicox S.A. Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
AU2006232517A1 (en) 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20090048219A1 (en) * 2005-05-23 2009-02-19 Nitromed Inc. Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US20070014839A1 (en) * 2005-07-18 2007-01-18 Stefan Bracht Decomposer film for transdermal patches
US20090018091A1 (en) * 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2007035940A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal norelgestromin delivery system
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
EP2308480B1 (en) 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
CA2624930A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
AU2006299383A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
EP1948221B1 (en) * 2005-11-02 2015-04-08 Syneron Medical Ltd. Human growth hormone patch formulations
US7888422B2 (en) * 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PL3295955T3 (pl) 2005-12-01 2021-10-25 University Of Massachusetts Lowell Nanoemulsje botulinowe
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
US20070202155A1 (en) * 2006-02-03 2007-08-30 Cure Therapeutics, Inc. Low dose no donor-containing transdermal patch
JP2009531443A (ja) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
EP2010169A4 (en) * 2006-04-10 2010-09-08 Nitromed Inc ASSESSMENT OF GENETIC RISK IN CARDIAC ERRORS: IMPACT OF THE GENETIC VARIATION OF THE POLYMORPHISM OF A G-PROTEIN BETA-3 SUB-UNIT
US20070259026A1 (en) * 2006-04-20 2007-11-08 Robert Ang Vasodialating dressing for use with intravenous catheters
DE102006019293A1 (de) * 2006-04-21 2007-10-25 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Pflaster, enthaltend ein Fentanyl Analogum
US8658391B2 (en) 2006-04-27 2014-02-25 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
US20090123527A1 (en) * 2006-07-24 2009-05-14 Akorn, Inc. Method of inducing topical anesthesia and transdermal patch
WO2008020039A2 (en) 2006-08-16 2008-02-21 Action Medicines, S.L. 2,5-dihydroxybenzene compounds for treating cancers and hematological dyscrasias
PT2292663E (pt) 2006-08-28 2013-11-04 Kyowa Hakko Kirin Co Ltd Anticorpos monoclonais humanos antagonistas específicos de light humano
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
CN101588802A (zh) * 2006-12-01 2009-11-25 日东电工株式会社 含有稳定化的多奈哌齐的贴剂
BRPI0719308A2 (pt) * 2006-12-01 2014-02-04 Nitto Denko Corp Método para supressão da coloração de preparação adesiva contendo donepzil e método para redução da quantidade de substâncias formadas relacionadas à donepezil.
JP2010528981A (ja) 2006-12-01 2010-08-26 アンテリオス， インコーポレイテッド 両親媒性実体ナノ粒子
AU2007353340A1 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
JP5227041B2 (ja) * 2007-02-28 2013-07-03 日東電工株式会社 薬物含有貼付製剤
JP2010520154A (ja) * 2007-03-05 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患のためのａｍｐａレセプターアンタゴニストおよびｎｍｄａレセプターアンタゴニスト
US20080226702A1 (en) * 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
WO2008139984A1 (en) * 2007-04-26 2008-11-20 Eisai R & D Management Co., Ltd. Cinnamide compounds for dementia
WO2008144320A2 (en) * 2007-05-17 2008-11-27 Endo Pharmaceuticals, Inc. Opioid and methods of making and using the same
CA2688415C (en) 2007-05-31 2015-11-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
RU2472539C2 (ru) 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
JP5358574B2 (ja) * 2007-08-17 2013-12-04 アルション セラピューティクス， インコーポレイテッド 高濃度の局所麻酔薬調合物
US9017301B2 (en) * 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
CN101902996B (zh) * 2007-10-15 2014-11-26 阿尔扎公司 芬太尼的一天更换一次透皮施用
JP5209433B2 (ja) * 2007-10-19 2013-06-12 日東電工株式会社 貼付製剤
CA2706465A1 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
EP2111857A1 (de) 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
PL3085381T3 (pl) 2008-05-21 2018-09-28 Ferring B.V. Ulegająca rozpadowi w ustach desmopresyna do zwiększania okresu snu niezakłócanego przez nokturię
US20110056863A1 (en) * 2008-05-30 2011-03-10 Junichi Sekiya Adhesive preparation containing donepezil, and package of the same
JP5421252B2 (ja) * 2008-05-30 2014-02-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 経皮吸収製剤
US20110212157A1 (en) 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US8235929B2 (en) * 2008-07-15 2012-08-07 Griffin Santea B Method of treating pruritis
US8119694B2 (en) * 2008-08-15 2012-02-21 Arcion Therapeutics, Inc. High concentration local anesthetic formulations
NZ593831A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
ES2727746T3 (es) 2009-01-06 2019-10-18 Galenagen Llc Composiciones orales para el tratamiento o la prevención de infecciones por E. Coli
AU2010204986B2 (en) 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2295046B1 (de) 2009-09-14 2012-12-19 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
DK2557924T3 (da) 2010-04-13 2019-09-23 Relmada Therapeutics Inc Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse
KR20130108406A (ko) 2010-11-02 2013-10-02 세키스이 메디칼 가부시키가이샤 첩부제
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
TR201905477T4 (tr) 2011-01-24 2019-05-21 Anterios Inc Nano-parçacık bileşimler.
WO2012103037A1 (en) 2011-01-24 2012-08-02 Anterios, Inc. Oil compositions
SG10201804552WA (en) 2011-01-24 2018-07-30 Anterios Inc Nanoparticle compositions, formulations thereof, and uses therefor
LT2683385T (lt) 2011-03-10 2018-10-25 Rigel Pharmaceuticals, Inc. 2,4 pakeistieji pirimidindiaminai, skirti naudoti sergant diskoidine vilklige
WO2012145651A2 (en) 2011-04-21 2012-10-26 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
CN103827113A (zh) 2011-06-23 2014-05-28 Map药物公司 新型氟麦角碱类似物
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
EP2599478A1 (de) 2011-11-30 2013-06-05 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
AU2012355983A1 (en) 2011-12-21 2015-01-22 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
ES2668300T3 (es) 2012-05-02 2018-05-17 Boehringer Ingelheim International Gmbh Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2013187965A1 (en) 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
WO2014012653A1 (en) * 2012-07-16 2014-01-23 Grünenthal GmbH Pharmaceutical patch for transdermal administration of tapentadol
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2014043257A1 (en) 2012-09-12 2014-03-20 Rigel Pharmaceuticals, Inc. Treatment for vitiligo
AU2013361340A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US9072682B2 (en) 2012-12-31 2015-07-07 Mylan Inc. Transdermal dosage form for low-melting point active agent
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
WO2015007326A1 (en) 2013-07-18 2015-01-22 Institut D'investigació Biomèdica De Bellvitge (Idibell) Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP2930238A1 (en) 2014-04-09 2015-10-14 Fundacio Centre de Regulacio Genomica Compositions for treating cancer
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
CA2947027A1 (en) 2014-05-01 2015-11-05 Anterios, Inc. Methods to treat, prevent, and improve skin conditions
EP2949324A1 (en) 2014-05-27 2015-12-02 Consorci Institut Catala de Ciencies Cardiovasculars Prevention and/or treatment of ischemia/reperfusion injury
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
EP2957634A1 (en) 2014-06-20 2015-12-23 Consejo Superior De Investigaciones Científicas Compounds for prevention and/or treatment of fibrotic diseases
EP2977463A1 (en) 2014-07-25 2016-01-27 Centro de Investigación Biomédica en Red (CIBER) Methods and agents related to lung diseases
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
EP2987503A1 (en) 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and reagents for prevention and/or treatment of infection
EP2997977A1 (en) 2014-09-19 2016-03-23 Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
ES2862701T3 (es) 2014-12-22 2021-10-07 Univ Rockefeller Anticuerpos agonistas anti-MERTK y usos de los mismos
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
EP3067369A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the treatment of anti-angiogenic resistant cancer
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
EP3289104B1 (en) 2015-04-29 2020-11-04 New York University Method for treating high-grade gliomas
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
KR20180031721A (ko) 2015-07-17 2018-03-28 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
AU2016300199B2 (en) 2015-07-24 2019-01-03 Glaxo Group Limited Treatment for vitiligo
KR102434314B1 (ko) 2015-09-01 2022-08-19 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
EP3356384B1 (en) 2015-09-29 2023-11-29 Paris Sciences et Lettres Polypeptides comprising vinculin binding sites for the treatment of proliferation and/or adhesion related diseases
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
JP2019513151A (ja) 2016-03-08 2019-05-23 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． カンプトテシン誘導体及びその使用
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
EP3219326A1 (en) 2016-03-14 2017-09-20 Institut Catalá De Ciencies Cardiovasculars (ICCC) Prevention and/or treatment of ischemia or ischemia/reperfusion injury
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
WO2017194789A1 (en) 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
US10653639B2 (en) 2016-05-16 2020-05-19 Cv Sciences, Inc. Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
FI127620B (fi) * 2016-07-12 2018-10-31 Tarmo Pekkarinen Nuuskantyyppinen nikotiini-pellavansiemenrouhekoostumus
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
US10660967B2 (en) 2016-10-21 2020-05-26 Augusta University Research Institute, Inc. Curcumin conjugates and methods of use thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CN110198703A (zh) 2016-11-21 2019-09-03 艾里奥治疗公司 大试剂的透皮递送
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
HRP20231579T1 (hr) 2016-12-07 2024-03-15 Agenus Inc. Anti-ctla-4 antitijela i postupci njihove upotrebe
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
IL298196A (en) 2017-02-17 2023-01-01 Eidos Therapeutics Inc Processes for the preparation of ag-10, its intermediates and salts
CN110662548A (zh) 2017-02-17 2020-01-07 卡姆瑞斯国际公司 通用抗毒液素
WO2018162581A1 (en) 2017-03-07 2018-09-13 OP2 Drugs Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
EP3385276A1 (en) 2017-04-03 2018-10-10 Targedys Proteins derived from clpb and uses thereof
CA3059366A1 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
DK3618863T3 (da) 2017-05-01 2023-08-21 Agenus Inc Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
BR112019025420A2 (pt) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. Compostos policíclicos e usos destes
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load
KR102574549B1 (ko) 2017-06-27 2023-09-07 주식회사 뉴라클사이언스 항-fam19a5 항체 및 이의 용도
KR20230142819A (ko) 2017-06-27 2023-10-11 주식회사 뉴라클사이언스 암 치료를 위한 항-fam19a5 항체의 용도
WO2019003159A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
EP3645044A4 (en) 2017-06-27 2021-04-28 Neuracle Science Co., Ltd USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
EP4265257A1 (en) 2017-09-01 2023-10-25 East Carolina University Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer
EP3569228A1 (en) 2018-05-17 2019-11-20 Association pour la recherche à l'IGBMC (ARI) Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof
ES2932076T3 (es) 2017-10-27 2023-01-11 Association Pour La Rech A Ligbmc Ari Moduladores agonistas de los receptores de glucocorticoides selectivos (SEGRAM) no esteroideos y usos de los mismos
MX2020004512A (es) 2017-10-31 2020-08-13 Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos.
WO2019100053A1 (en) 2017-11-20 2019-05-23 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2α to improve muscle generation and repair
MX2020006424A (es) 2017-12-20 2021-01-08 Allergan Inc Polipéptidos de dominio de unión a células de toxina botulínica y métodos de uso para el rejuvenecimiento de la piel.
US20210137960A1 (en) 2018-02-01 2021-05-13 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
EP3539975A1 (en) 2018-03-15 2019-09-18 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Micropeptides and uses thereof
EP3768841A4 (en) 2018-03-23 2021-12-08 Eidos Therapeutics, Inc. METHODS OF TREATING TTR AMYLOSIS USING AG10
WO2019207513A1 (en) 2018-04-24 2019-10-31 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
AU2019265888A1 (en) 2018-05-10 2020-11-26 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2020016459A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
BR112020026493A2 (pt) 2018-08-17 2021-03-23 Eidos Therapeutics, Inc. Formulações de ag10
AU2019336943A1 (en) 2018-09-06 2021-03-18 OP2 Drugs Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof
EP3849540A1 (en) 2018-09-13 2021-07-21 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
MX2021002995A (es) 2018-09-13 2021-07-15 Eirion Therapeutics Inc Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos.
JP2022504287A (ja) 2018-10-03 2022-01-13 スターテン・バイオテクノロジー・ベー・フェー ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法
CA3119341A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20220031595A1 (en) 2018-12-03 2022-02-03 Eirion Therapeutics, Inc. Improved delivery of large agents
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
EP3921038A1 (en) 2019-02-06 2021-12-15 Dice Alpha, Inc. Il-17a modulators and uses thereof
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
BR112021022619A2 (pt) 2019-05-14 2022-01-04 Eirion Therapeutics Inc Retardo de efeito de pico e/ou prolongamento de duração de resposta
EP3959293A4 (en) 2019-05-20 2022-12-28 NIRvana Sciences Inc. LOW EMISSION DYES, COMPOSITIONS THEREOF, AND PROCESSES FOR THEIR PREPARATION AND USE
JP2022545741A (ja) 2019-08-30 2022-10-28 アジェナス インコーポレイテッド 抗ｃｄ９６抗体およびその使用方法
WO2021055376A1 (en) 2019-09-16 2021-03-25 Dice Alpha, Inc. Il-17a modulators and uses thereof
US20240166770A1 (en) 2019-10-18 2024-05-23 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US11850220B2 (en) 2020-05-19 2023-12-26 Augusta University Research Institute, Inc. Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR20230098201A (ko) 2020-10-26 2023-07-03 네오이뮨텍, 인코퍼레이티드 줄기 세포 동원의 유도 방법
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
AU2021376396A1 (en) 2020-11-05 2023-06-08 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
US11858908B2 (en) 2021-01-19 2024-01-02 Augusta University Research Institute, Inc. Compositions and methods for inhibiting IDO1
WO2022192545A1 (en) 2021-03-10 2022-09-15 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
AU2022293999A1 (en) 2021-06-14 2023-11-30 argenx BV Anti-il-9 antibodies and methods of use thereof
EP4308088A1 (en) 2021-11-08 2024-01-24 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2024086852A1 (en) 2022-10-21 2024-04-25 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
EP0223524B1 (en) * 1985-11-08 1991-10-23 Nitto Denko Corporation Use of adhesive dermal bandages and dermal percutaneous preparations
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5164416A (en) * 1989-02-03 1992-11-17 Lintec Corporation Transdermal therapeutic formulation containing a limonene
BR9008012A (pt) * 1990-03-28 1992-12-01 Noven Pharma Metodo e dispositivo para a liberacao de drogas para a pele
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
JP3202777B2 (ja) * 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤

Also Published As

Publication number Publication date
CA2245366C (en) 2001-11-27
DE19837902B4 (de) 2013-11-07
GB9817489D0 (en) 1998-10-07
CA2245366A1 (en) 1999-02-21
DE19837902A1 (de) 1999-02-25
ITMI981889A1 (it) 2000-02-12
GB2328375A (en) 1999-02-24
GB2328375B (en) 2001-09-19
IT1302020B1 (it) 2000-07-20
US5948433A (en) 1999-09-07

Similar Documents

Publication Publication Date Title
ITMI981889A0 (it) Cerotto transdermico
ATE220545T1 (de) Fentanyl enthaltendes transdermal-pflaster
NO982686D0 (no) R°rledningsplugg
DE59807782D1 (de) Punktionsset
DE69822555D1 (de) Schuhwerk
DE69801399T2 (de) Urladen
DE69801831T2 (de) Spreizvorrichtung
DE29723219U1 (de) Erdanker
DE69833024D1 (de) Dachrinne
NO20002555D0 (no) Skjøt
FR2772563B1 (fr) Pantoufle cousue
DE29722394U1 (de) Arbeitsgerät
DE9415058U1 (de) Fersenpflaster
NO974892L (no) Ventilasjonsr°r
DE29719002U1 (de) Vertikutiergerät
DE29816777U1 (de) Rangierverteiler
FR2770103B1 (fr) Bigoudi perfectionne
DE29706512U1 (de) Hausschuh
DE29712457U1 (de) Rollrasen
DE29623364U1 (de) Pflasterabstandhalter
IT1293425B1 (it) Cerotto transcutaneo
DE29808003U1 (de) Rangierverteiler
KR970020511U (ko) 슬리퍼
DE29720721U1 (de) Hausschuh
DE29710418U1 (de) Verankerung

Legal Events

Date Code Title Description
0001 Granted